Boston Scientific Co. (NYSE:BSX) Stock Holdings Reduced by Tocqueville Asset Management L.P.

Tocqueville Asset Management L.P. lowered its position in Boston Scientific Co. (NYSE:BSX) by 1.1% during the fourth quarter, HoldingsChannel.com reports. The firm owned 496,912 shares of the medical equipment provider’s stock after selling 5,446 shares during the quarter. Tocqueville Asset Management L.P.’s holdings in Boston Scientific were worth $44,384,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Harbour Investments Inc. boosted its stake in shares of Boston Scientific by 11.5% during the 3rd quarter. Harbour Investments Inc. now owns 2,817 shares of the medical equipment provider’s stock worth $236,000 after acquiring an additional 291 shares in the last quarter. OneDigital Investment Advisors LLC boosted its stake in shares of Boston Scientific by 3.2% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 10,177 shares of the medical equipment provider’s stock worth $853,000 after acquiring an additional 311 shares in the last quarter. Empowered Funds LLC boosted its stake in shares of Boston Scientific by 7.9% during the 3rd quarter. Empowered Funds LLC now owns 23,413 shares of the medical equipment provider’s stock worth $1,962,000 after acquiring an additional 1,715 shares in the last quarter. Mizuho Markets Americas LLC bought a new stake in shares of Boston Scientific during the 3rd quarter worth about $739,000. Finally, Schear Investment Advisers LLC boosted its stake in shares of Boston Scientific by 9.6% during the 3rd quarter. Schear Investment Advisers LLC now owns 19,770 shares of the medical equipment provider’s stock worth $1,657,000 after acquiring an additional 1,727 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on BSX. JPMorgan Chase & Co. upped their price target on Boston Scientific from $100.00 to $110.00 and gave the stock an “overweight” rating in a research note on Monday, December 16th. Truist Financial upped their price target on Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. Needham & Company LLC reissued a “hold” rating on shares of Boston Scientific in a research report on Monday, March 3rd. Citigroup boosted their price objective on Boston Scientific from $107.00 to $122.00 and gave the stock a “buy” rating in a research report on Thursday, February 6th. Finally, Barclays boosted their price objective on Boston Scientific from $111.00 to $118.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. Two investment analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Boston Scientific currently has a consensus rating of “Moderate Buy” and an average price target of $108.91.

Boston Scientific Stock Up 2.0 %

NYSE BSX opened at $97.26 on Monday. The firm has a market cap of $143.53 billion, a PE ratio of 77.81, a price-to-earnings-growth ratio of 2.79 and a beta of 0.77. Boston Scientific Co. has a one year low of $66.16 and a one year high of $107.17. The stock’s 50 day simple moving average is $101.05 and its 200 day simple moving average is $91.84. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. As a group, sell-side analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Boston Scientific news, EVP John Bradley Sorenson sold 4,119 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total value of $370,792.38. Following the transaction, the executive vice president now directly owns 35,319 shares in the company, valued at approximately $3,179,416.38. This trade represents a 10.44 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward J. Ludwig sold 12,000 shares of the stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $105.48, for a total value of $1,265,760.00. Following the completion of the transaction, the director now owns 24,398 shares in the company, valued at $2,573,501.04. The trade was a 32.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 137,302 shares of company stock worth $14,319,269 in the last three months. Insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.